« Back
Home /
Girentuximab

Girentuximab

Item no.	HY-P99023-10mg
Manufacturer	MedChem Express
CASRN	916138-87-9
Amount	10 mg
Quantity options	10 mg 1 mg 5 mg
Category	Antibodies In Vivo Antibodies
Type	Biosimilars
Specific against	other
Purity	99.90
Dry ice	Yes
Citations	[1]Chamie K, et al. Adjuvant Weekly Girentuximab Following Nephrectomy for High-Risk Renal Cell Carcinoma: The ARISER Randomized Clinical Trial. JAMA Oncol. 2017;3(7):913-920.
Smiles	[Girentuximab]
ECLASS 10.1	42030590
ECLASS 11.0	42030590
UNSPSC	12352203
Alias	G250, cG250
Shipping condition	Dry ice
Available
Manufacturer - Type	Inhibitory Antibodies
Manufacturer - Applications	Cancer-programmed cell death
Manufacturer - Targets	Carbonic Anhydrase
Shipping Temperature	Dry Ice
Storage Conditions	Store at -80°C for 2 years
Product Description	Girentuximab (G250) is a chimeric monoclonal antibody that binds carbonic anhydrase IX (CAIX), a cell surface glycoprotein ubiquitously expressed in clear cell renal cell carcinoma (ccRCC)[1].
Manufacturer - Research Area	Cancer
Solubility	H2O
Manufacturer - Pathway	Metabolic Enzyme/Protease
Isoform	CA Ⅸ
Clinical information	Phase 3

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-P99023-10mg-safety-datasheet.pdf